Regulation makers, and also other stakeholders in society, may be skeptical about re-dispensing returned medicines with no good validation [sixteen]. This section describes how most recent technologies gathered with the literature evaluation can permit the reuse of returned medicines in accordance with the two teams of stakeholder requirements for